Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma

BACKGROUND: Data on sequential therapy in patients with metastatic renal cell carcinoma (mRCC) and intrinsic resistance to receptor tyrosine kinase inhibitor (rTKI) treatment remains vague. METHODS: We retrospectively studied treatment characteristics and outcome of mRCC patients refractory to first...

Descripción completa

Detalles Bibliográficos
Autores principales: Busch, Jonas, Seidel, Christoph, Weikert, Steffen, Wolff, Ingmar, Kempkensteffen, Carsten, Weinkauf, Lisa, Hinz, Stefan, Magheli, Ahmed, Miller, Kurt, Grünwald, Viktor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154177/
https://www.ncbi.nlm.nih.gov/pubmed/21756335
http://dx.doi.org/10.1186/1471-2407-11-295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154177/
https://www.ncbi.nlm.nih.gov/pubmed/21756335
http://dx.doi.org/10.1186/1471-2407-11-295

Ejemplares similares